POST Online Media Lite Edition



 

Indonesia suspends distribution of batch of AstraZeneca COVID-19 vaccine

Christian Fernsby |
Indonesia has suspended distribution of a batch of AstraZeneca PLC’s novel coronavirus vaccine to run tests for sterility and toxicity following the death of a 22-year-old man a day after immunization, the health ministry said on Sunday.

Article continues below




The “CTMAV547” batch consists of 448,480 vaccine doses that arrived in the Southeast Asian nation last month - part of a delivery of more than 3.85 million doses from the COVAX Facility, backed by the World Health Organization.

Some of the doses have been distributed in the capital city Jakarta and the province of North Sulawesi, as well as given to the military, the ministry said in a statement.

A national committee in charge of monitoring effects of novel coronavirus vaccination launched an investigation earlier this month after a 22-year-old man in Jakarta died a day after receiving an AstraZeneca shot.

The man received his dose from the CTMAV547 batch, health ministry spokeswoman Siti Nadia Tarmizi told Reuters.

“This is a form of caution by the government to ensure the safety of this vaccine,” she said in a statement, adding that distribution of other batches of AstraZeneca vaccines will not be affected.

The batch test could take at least two weeks, said the head of the vaccine monitoring committee, Hindra Irawan Satari.

“After it is proven that it is sterile and does not contain toxins, the use of the vaccine will be resumed. The fastest we can get the results will be in two weeks,” he said.


What to read next

World-first COVID-19 alternating dose vaccine study launches in UK
Canada suspends AstraZeneca vaccine for adults 55 and under
Under-40s in UK to be offered alternative to AstraZeneca jab